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Ⅰ．Introduction
 Acute spinal cord injury （SCI） is generally divided 
into two chronological stages, primary and secondary 
injury. The primary injury is tissue destruction induced 
by mechanical stress to the spinal cord. The secondary 
injury is a pathophysiological reaction of the spinal cord 
that is triggered by the primary injury. The secondary 
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SUMMARY
To elucidate neuroprotective effect of granulocyte colony-stimulating factor （G-CSF） for acute 
spinal cord injury （SCI）, we performed experimental studies and early phase of clinical trials. 
The results of experimental studies showed that G-CSF exerts neuroprotective effects for acute SCI 
via mobilization of bone marrow-derived cells into injured spinal cord, suppression of neuronal apoptosis, 
suppression of inflammatory cytokine up-regulation, suppression of oligodendrocyte apoptosis and 
promotion of angiogenesis. 
Next we moved to clinical trial. In a phase I/IIa trial, no adverse events were observed. Then, we 
conducted a non-randomized, non-blinded, comparative trial, which suggested the efficacy of G-CSF for 
promoting neurological recovery. We are now preparing a phase III trial to confirm G-CSF treatment 
efficacy for acute SCI. The current trial will include cervical SCI within 48 hours after injury. Patients 
will be randomly assigned to G-CSF and placebo groups and evaluated by double blinded manner. 
Our primary endpoint is changes in American Spinal Injury Association motor scores from baseline 
to 3 months. Each group will include 44 patients （88 total patients）. After completion of this clinical 
trial, pharmaceutical approval will be applied for health insurance publication. G-CSF-mediated 
neuroprotection is a promising candidate for a novel therapeutic approach for SCI.
　Key words:  G-CSF, spinal cord injury, neuroprotection, clinical trial
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SCI results in hemorrhage, destruction of the blood-
spinal cord barrier, excitotoxicity, electrolyte shift, 
calcium influx, infiltration of inflammatory cells and 
an inflammatory reaction dependent upon the release 
of pro-inflammatory cytokines, all of which can induce 
cell death resulting in spread of the damaged area. 
Extensive laboratory and clinical studies have examined 
mechanisms to suppress the secondary injury because it 
has the potential to respond to treatment［1］.
 Based on the Second National Acute Spinal 
Cord Injury Study, the administration of high-dose 
methylprednisolone sodium succinate （MPSS） was 
established as a standard treatment for patients with 
acute SCI［2］. However, several recent studies have 
indicated that high-dose MPSS therapy could promote 
only modest neurological recovery［3］and frequently 
induces side effects in the respiratory system and 
digestive organs［4］. Recently published guidelines 
for SCI revealed that treatment with steroids is not 
recommended. Therefore, the development of new 
therapeutic drugs for SCI is greatly needed［5］.
 Granulocyte colony-stimulating factor （G-CSF） is 
a 19.6-kDa glycoprotein best known as a growth factor 
for hematopoietic progenitor cells, and is clinically used 
to treat neutropenia and to mobilize peripheral blood-
derived hematopoietic stem cells for transplantation
［6,7］. Recent experimental studies have indicated that 
G-CSF also has non-hematopoietic functions and can 
potentially be used for the treatment of neuronal injury, 
including stroke and neurodegenerative diseases［8-12］.
 Thus, we hypothesized that the administration of 
G-CSF is neuroprotective for acute SCI, and examined 
this hypothesis using a rodent model of SCI. 
Ⅱ．Basic Research
Bone marrow mobilization
 To elucidate the effects of G-CSF-mediated 
mobilization of bone marrow-derived stem cells 
on the injured spinal cord, we performed in vivo 
experiments using bone marrow chimeric mice. 
Bone marrow cells obtained from green fluorescent 
protein （GFP） transgenic mice were transplanted 
into lethally irradiated C57BL/6 mice. Four weeks 
after bone marrow transplantation, SCI was induced 
by a static load （20 g, 5 min） at the T8 level. G-CSF 
（200μg/kg/day） was injected subcutaneously for 5 
days. Immunohistochemistry for GFP and cell lineage 
markers was performed to evaluate G-CSF-mediated 
mobilization of bone marrow-derived cells into injured 
spinal cord. Hind limb locomotor recovery was assessed 
for 6 weeks. 
 Immunohistochemistry revealed that G-CSF 
increased the number of GFP-positive cells in injured 
spinal cord, indicating that bone marrow-derived cells 
were mobilized and migrated into the injured spinal 
cord. The numbers of double-positive cells for GFP 
and glial markers were larger in the G-CSF-treated 
mice than in the control mice. Luxol Fast Blue staining 
revealed that G-CSF promoted sparing of the white 
matter. G-CSF-treated mice showed significant recovery 
of hind limb function compared with control mice. 
 These results support previous findings that G-CSF 
showed efficacy for the treatment of SCI through the 
mobilization of bone marrow-derived cells［13］.
Anti-apoptotic effect of G-CSF on spinal cord neuron
 To elucidate the anti-apoptotic effect of G-CSF 
on spinal cord neurons, we performed in vitro and in 
vivo experiments. The addition of G-CSF suppressed 
glutamate-induced cell death of cultured cerebellar 
granule neurons in vitro.  Moreover, we used a 
mouse model of compressive SCI to examine the 
neuroprotective potential of G-CSF in vivo. Histologic 
assessment using cresyl violet staining revealed that 
the number of surviving neurons in the injured spinal 
cord was significantly increased in G-CSF-treated mice 
compared with control mice. Immunohistochemistry 
also revealed that G-CSF suppressed neuronal apoptosis 
after SCI. Moreover, the administration of G-CSF 
promoted hind limb functional recovery. Examination of 
signaling pathways downstream of the G-CSF receptor 
suggests that G-CSF might promote functional recovery 
by inhibiting neuronal apoptosis after SCI［14］. 
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significantly higher compared with the control group. 
The G-CSF-treated group showed significantly greater 
recovery of hind limb function than the control group. 
G-CSF exerts neuroprotective effects via promotion of 
angiogenesis after SCI［16］.
Ⅲ．Early phase clinical trial
Safety and feasibility trial
 To confirm the safety and feasibility of G-CSF 
administration for acute SCI, we have initiated a phase 
I/IIa clinical trial of neuroprotective therapy using 
G-CSF. The trial included a total of 16 SCI patients 
within 48 h of onset. In the first step, G-CSF （5μg/kg/
day） was intravenously administered for 5 consecutive 
days to five patients. In the second step, G-CSF （10μg/
kg/day） was similarly administered to 11 patients. We 
evaluated motor and sensory functions of patients using 
the American Spinal Cord Injury Association （ASIA） 
score and ASIA impairment scale （AIS） grade. In all 
16 patients, neurological improvement was obtained 
after G-CSF administration. AIS grade increased by 
one step in nine of 16 patients. A significant increase in 
ASIA motor scores was detected 1 day after injection 
（P＜0.01）, and both light touch and pin-prick scores 
improved 2 days after injection （P＜0.05） in the 10-μg 
group. No severe adverse effects were observed after 
G-CSF injection. These results indicate that intravenous 
administration of G-CSF （10μg/kg/day） for 5 days is 
essentially safe, and suggests that some neurological 
recovery can occur in most patients. We suggest that 
G-CSF administration could be therapeutic for patients 
with acute SCI［17］.
Non-randomized, non-blinded controlled trial
 Next we conducted a multicenter prospective, non-
randomized, non-blinded, controlled clinical trial to 
assess the preliminary efficacy and feasibility of G-CSF 
therapy for patients with acute SCI. The trial ran from 
August 2009 to March 2011, and included 41 patients 
with SCI treated within 48 hours of onset. Informed 
consent was obtained from all patients. After providing 
consent, patients were divided into two groups. In 
Anti-apoptotic effect of G-CSF on oligodendrocytes
 Next, we performed in vivo experiments to elucidate 
the effect of G-CSF for oligodendrocyte apoptosis 
after SCI. Contusive SCI was induced in adult female 
Sprague-Dawley rats using the Infinite Horizon 
Impactor （magnitude: 200 kilodyne）. Recombinant 
human G-CSF （15.0μg/kg） was administered by tail 
vein injection at 1 h after surgery and daily the next 4 
days. The vehicle control rats received equal volumes of 
normal saline at the same time points. Real-time reverse 
transcriptase polymerase chain reaction （RT-PCR） and 
western blot analysis revealed that G-CSF suppressed 
the expression of pro-inflammatory cytokines （IL-1 
beta and TNF- alpha） at both the mRNA and protein 
levels. Histological assessment with Luxol Fast Blue 
staining revealed that the area of white matter that was 
spared in the injured spinal cord was significantly larger 
in G-CSF-treated rats. Immunohistochemical analysis 
showed that G-CSF promoted the upregulation of the 
anti-apoptotic protein Bcl-Xl in oligodendrocytes, 
suppressing apoptosis after SCI. Moreover, G-CSF 
administration promoted better functional recovery of 
hind limbs. G-CSF protects oligodendrocytes from SCI-
induced cell death via the suppression of inflammatory 
cytokines and up-regulation of anti-apoptotic proteins. 
As a result, G-CSF attenuates white matter loss and 
promotes hind limb functional recovery［15］.
Promotion of angiogenesis
 A contusive SCI rat model was used and the 
animals were randomly allocated to either a G-CSF 
treatment group or a control group. The integrity of the 
blood-spinal cord barrier was evaluated by measuring 
the degree of edema in the cord and the volume of 
extravasation. For histological evaluation, cryosections 
were immunostained with anti-von Willebrand factor 
and the number of vessels was counted to assess 
revascularization. Real-time RT-PCR was performed 
to assess the expression of angiogenic cytokines, and 
recovery of motor function was assessed with functional 
tests. In the G-CSF-treated rats, the total number 
of vessels with a diameter ＞20μm was markedly 
larger and the expression of angiogenic cytokines was 
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the G-CSF group （17 patients）, G-CSF （10μg/kg/
d） was intravenously administered for 5 consecutive 
days, and in the control group （24 patients）, patients 
were similarly treated but did not receive G-CSF. We 
evaluated motor and sensory functions using the ASIA 
score and AIS at 1 week, 3 months, 6 months, and 1 
year after onset. Only two patients did not experience 
AIS improvement in the G-CSF group. In contrast, 15 
patients in the control group did not experience AIS 
improvement. In the analysis of ASIA motor score, 
there was a significant difference between the G-CSF 
and the control groups in increased ASIA motor score 1 
year after SCI （mean, 30.5±20.8 points in the G-CSF 
group, 15.7±16.4 in the control group, P＜0.05, Fig. 
1）. Despite the study limitation that patient selection 
was not randomized, the present results suggest the 
possibility that G-CSF administration has beneficial 
effects on neurological recovery in patients with acute 
SCI［18］.
Ⅳ．Current trial
 Based on the results of basic research and the early 
phase clinical trial, we planned to perform a prospective, 
randomized, double-blind, placebo-controlled clinical 
trial to confirm the therapeutic effects of G-CSF 
for acute SCI. Our protocol was approved by the 
Pharmaceuticals and Medical Device Agency and the 
trial will be funded by the Center for Clinical Trials, 
Japan Medical Association.
 The current trial will include cervical SCI （severity 
of AIS B/C） within 48 hours after injury. Patients 
will be re-assessed for neurological status at 48 hours 
after injury, and those whose palsy is AIS B/C will be 
enrolled. Patients with neurological recovery to AIS D 
will be excluded. Patients will be randomly assigned 
to G-CSF and placebo groups. The G-CSF group will 
be administered 400μg/m2/d G-CSF for 5 days via 
intravenous infusion in normal saline for 5 consecutive 
days. The placebo group will be similarly administered 
a placebo （Fig. 2）.
 Allocation will be concealed between blinded 
evaluators of efficacy/safety and those performing the 
laboratory analysis, because G-CSF markedly increases 
white blood cell counts, which can reveal patient 
treatment. Our primary endpoint will be changes in 
ASIA motor scores from baseline to 3 months after 
administration. Each group will include 44 patients （88 
total patients）.
 After completion of this clinical trial, pharmaceutical 
approval will be applied for health insurance publication. 
G-CSF-mediated neuroprotection is a promising 
candidate for a novel therapeutic approach for SCI.
Fig. 1 Result of multicenter prospective, non-randomized, 
non-blinded, controlled clinical trial to assess the 
preliminary efficacy and feasibility of G-CSF 
therapy for patients with acute SCI. There was a 
significant difference between the G-CSF and the 
control groups in increased ASIA motor score 1 
year after SCI （mean, 30.5±20.8 points in the 
G-CSF group, 15.7±16.4 in the control group, P＜
0.05）.
Fig. 2 Study design outline of the protocol of a 
prospective, randomized, double-blind, placebo-
controlled clinical trial to confirm the therapeutic 
effects of G-CSF for acute SCI.
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